← Back to Search

Antiplatelet agent

Tricagrelor for Bleeding

Phase 4

Waitlist Available

Led By Mandeep Singh, MD

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, approximately 90 days.

Awards & highlights

Study Summary

This trial is testing whether it is safe to reduce the time patients are on two blood-thinning medications after having a coronary stent placed.

Eligible Conditions

Bleeding Complications

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, approximately 90 days.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, approximately 90 days.

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, approximately 90 days. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Ischemic Risk Post-PCI in High Bleed Risk Patients With Genotype-guided Single Antiplatelet Therapy

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Genotype-Guided TherapyExperimental Treatment2 Interventions

Subjects with high bleeding risk (HBR) on dual antiplatelet therapy (DAPT) with clopidogrel and aspirin, that have undergone successful percutaneous coronary intervention (PCI) will be stratified by the CYP2C19 loss-of-function (LOF) allele within one week of DAPT initiation. In this group, subjects identified as CYP2C19*2 or*3 LOF allele carrier will be given prasugrel or ticagrelor monotherapy.

Group II: Conventional TherapyActive Control1 Intervention

Subjects with high bleeding risk (HBR) on dual antiplatelet therapy (DAPT) with clopidogrel and aspirin, that have undergone successful percutaneous coronary intervention (PCI) will be stratified by the CYP2C19 loss-of-function (LOF) allele within one week of DAPT initiation. In this group, subjects identified as CYp2C19*2 or*3 LOF allele non-carriers will continue with clopidogrel monotherapy.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Prasugrel

FDA approved

Tricagrelor

2022

Completed Phase 4

~100

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor

3,234 Previous Clinical Trials

3,771,758 Total Patients Enrolled

5 Trials studying Bleeding

14,176 Patients Enrolled for Bleeding

Mandeep Singh, MDPrincipal InvestigatorMayo Clinic

5 Previous Clinical Trials

240 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals have enrolled in the research trial?

"Confirmed. The clinical trial is actively recruiting according to the data hosted on clinicaltrials.gov, which was first posted on March 29th 2022 and most recently updated October 24th 2022. 150 prospective participants are needed from a single medical facility."

Answered by AI

Is enrollment in this research study still a viable option for those seeking treatment?

"Affirmative. Details obtained from clinicaltrials.gov demonstrate that the clinical trial, which was first advertised on March 29th 2022, is actively recruiting patients. 150 volunteers are required at a single location to participate in this research endeavour."

Answered by AI